Author(s)

Jaana Korpela, Pekka Mali, Anne Kaljonen, Eeva Salminen

.

This phase II study assessed the clinical response and short-term quality of life of patients receiving first-line chemotherapy with epirubicin-docetaxel combination for metastatic breast cancer. Thirty-one breast cancer patients were treated with epirubicin (75 mg/m² for 15 minutes) followed one hour later by a one-hour infusion of docetaxel (75 mg/m²) q3w. EORTC QLQ-C30 and EORTC QLQ-BR23 forms were filled in at baseline, and at the second and eighth cycle of chemotherapy. The combination of epirubicin and docetaxel provided a high degree of clinical benefit. Clinical response was observed in 17 patients (55%), including five (16%) complete responses and 12 (39%) partial responses. Of responding and stable patients 23 (74%) maintained the same status for at least six months (clinical benefit). The mean survival time was 40.8 months. During the treatment the emotional functioning improved and the concerns about the future were relieved. Some aspects of quality of life were impaired, with slightly decreased physical and cognitive functioning, distress related to body image and hair loss, and adverse effects of chemotherapy. Overall, the global quality of life was maintained.

Metastatic Breast Cancer, Chemotherapy, Epirubicin, Docetaxel, Quality of Life

J. Korpela, P. Mali, A. Kaljonen and E. Salminen, "Quality of Life of Patients with Metastatic Breast Cancer Treated with Epirubicin and Docetaxel," International Journal of Clinical Medicine, Vol. 2 No. 3, 2011, pp. 346-351. doi: 10.4236/ijcm.2011.23060.